A systematic review of dosing frequency with bone-targeted agents for patients with bone metastases from breast cancer

BACKGROUND: Bone-targeted agents are usually administered to breast cancer patients with bone metastases every 3–4 weeks. Less frequent (‘de-escalated’) treatment may provide similar benefits with improved safety and reduced cost. METHODS: To systematically review randomised trials comparing de-esca...

Descripción completa

Detalles Bibliográficos
Autores principales: Hutton, Brian, Addison, Christina L., Campbell, Kaitryn, Fergusson, Dean, Mazarello, Sasha, Clemons, Mark
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2013
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4723383/
https://www.ncbi.nlm.nih.gov/pubmed/26909282
http://dx.doi.org/10.1016/j.jbo.2013.05.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4723383/
https://www.ncbi.nlm.nih.gov/pubmed/26909282
http://dx.doi.org/10.1016/j.jbo.2013.05.001

Ejemplares similares